A bit of good news might be coming soon for the 425 million people worldwide with type 2 diabetes who have to take multiple medicines to control their condition.
The U.S. Food and Drug Administration has accepted a new drug application by Ridgefield-based Boehringer Ingelheim and Eli Lilly and Co. for a fixed-dose combination tablet.